NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment
Why Kymera Therapeutics Stock Is Back In Focus After A C-suite Change
Kymera Therapeutics (KYMR) is in focus after appointing Terence Rooney, MD, as Chief Medical Officer, a change that puts fresh attention on how the company plans its future clinical development work.
See our latest analysis for Kymera Therapeutics.
Kymera Therapeutics shares trade at US$103.40 after short term share price weakness, with the stock down 3.37% over one day and 9.46% over 30 days, although a 28.11% 90 day share...